ArticleDigital health
Evaluation of a pharmacist-led digital hypertension management program in a tertiary hospital in Singapore.
Article in Digital health. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To determine if a pharmacist-led digital enablement for medication optimization (DEMO) program was non-inferior to standard physician consultation in achieving a blood pressure (BP) target of <140/90mmHg within six months. Secondary outcomes included assessing BP changes and time to exit in DEMO group, system usability scale (SUS), and willingness to pay (WTP) for the DEMO program. Methods: A prospective cohort study was conducted in a hospital outpatient setting (Mar 2023 -Oct 2024). The intervention group used a mobile application to transmit home BP readings to a clinical dashboard, with pharmacist-led teleconsultations every 2 - 4 weeks, during which antihypertensives were adjusted. Control group received standard physician consultations. Results: Using 1:4 nearest neighbour propensity score matching, 145 control patients were matched to 56 DEMO participants. The probability of achieving BP <140/90mmHg within six months was 53% (95% CI 44-62) in DEMO vs 39% (95% CI 31-47) in controls. DEMO participants had a 36% higher relative probability of achieving the BP target (RD 0.14, 95% CI 0.01-0.27; P=0.041). Mean change in systolic and diastolic BP in DEMO group was -16.4mmHg (95% CI -21.9 to -10.9; P<0.001) and of -7.7mmHg (95% CI -10.5 to -4.9; P<0.001) respectively. Median time to exit DEMO was 46 days (IQR 20.5-74). Mean SUS was 82.2±13.7, indicating excellent usability. Mean WTP was SGD$13.2 per month (95% CI 0-32.0). Conclusion: The pharmacist-led DEMO program was non-inferior to standard physician consultation in achieving a BP target of 140/90mmHg within six months, with high usability and modest WTP.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.